- Grants and collaborations to support development
Pluristem now has three ongoing clinical programs: critical limb ischemia (CLI, Phase III), intermittent claudication (IC, Phase II) and the acute radiation syndrome program (ARS, primates), which was recently expanded due to the participation of the US Department of Defense (DOD). Many of the costs of these programs have been offset, for instance due to NIH support of the ARS program as well as new grants of $16.6m to study PLX-PAD. The company recently received FDA and EMA sign-offs on a Phase III study in femoral neck fracture, which we expect to start shortly.Pluristem Therapeutics is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The company's product candidates include: PLX-PAD, which is in a multinational clinical trial in critical limb ischemia, and in a multinational clinical trial in recovery following surgery for hip fracture; PLX-R18, which is under development in the U.S. for acute radiation syndrome, as well as in a trial in the U.S. and Israel for incomplete hematopoietic recovery following hematopoietic cell transplantation; and PLX-Immune, which is under pre-clinical development for treatment of certain human cancer types.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.